Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Fibrinolysis Stories

2014-03-24 23:26:03

Markets Research Reports.biz added deep and professinal market research reports on "China Grape Wine Manufacturing Industry, 2014" Market Analysis and Overview. Visit: http://www.marketresearchreports.biz/analysis-details/china-grape-wine-manufacturing-industry-2014. Albany, NY (PRWEB) March 24, 2014 China Grape Wine Manufacturing Industry, 2014 China grape wine manufacturing industry, 2014 is valuable for anyone who wants to invest in the grape wine manufacturing industry to...

2014-03-04 08:32:11

REHOVOT, Israel, March 4, 2014 /PRNewswire/ -- D-Pharm Ltd (TASE: DPRM) announced today, March 4th, 2014, the successful interim analysis of the first group of stroke patients that completed follow-up in the Phase 2 clinical study of THR-18. The interim report confirms the safety and tolerability of THR-18 at a dose of 0.18mg/kg, administered together with tissue plasminogen activator (tPA) in acute ischemic stroke patients. The interim report gives a green light to proceed to...

2013-10-16 08:27:57

REHOVOT, Israel, October 16, 2013 /PRNewswire/ -- D-Pharm Ltd (TASE: DPRM) announced today, October 16th 2013, receipt of approval from the regulatory authorities in the Ukraine to commence a Phase IIa clinical study of THR-18, to be given with the clot buster drug tissue plasminogen activator (tPA), in patients with acute ischemic stroke. THR-18 is a synthetic therapeutic peptide derived from plasminogen activator inhibitor-1 (PAI-1). This is a double-blind,...

2013-07-23 08:31:28

-- Augments Fully Automated Assay Menu for the Detection of Fibrinolytic Disorders -- BEDFORD, Mass., July 23, 2013 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of the HemosIL FDP assay as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices. The assay will be commercialized in countries throughout Europe, Asia, and other international markets. FDP is an immunoturbidimetric assay designed for the detection...

2012-12-19 08:25:21

MARBURG, Germany, Dec. 19, 2012 /PRNewswire/ -- Clinical study results published today in the journal Anesthesiology showed that human fibrinogen concentrate can significantly reduce the need for blood transfusion when given as an intra-operative, targeted first-line hemostatic therapy in bleeding patients undergoing aortic replacement surgery. The Phase II prospective study, performed by CSL Behring and collaborators at the Hannover Medical School, Germany, enrolled 61 patients to assess...

2012-04-14 23:00:27

Swanson Health Products now offers Swanson Ultra Maximum Strength Nattokinase for cardiovascular wellness. This new formula features patented NSK-SD® Japanese Nattokinase for super potent circulatory support. Fargo, ND (PRWEB) April 13, 2012 Nattokinase is an enzyme extracted from natto, a traditional dish from Japan made of fermented soybeans. The enzyme harvested is “fibrinolytic” and is shown to promote healthy blood flow to support cardiovascular and circulatory health....

2012-03-09 00:56:00

Everyone is familiar with the pain of skinned knees. However, the complex pathway of proteins that works behind the scenes after the bleeding has stopped is not as well known. Central to this process is the production of plasmin, a powerful blood enzyme that disposes of blot clots. Doctors also harness the "clot busting" abilities of plasmin to treat patients who suffer heart attack or stroke. Now, a study published by Cell Press on March 8th in the journal Cell Reports provides remarkable...

2012-03-09 00:53:28

By discovering how a blood clot-busting enzyme is switched on, researchers have unlocked a century-old atomic riddle that could lead to new treatments for clotting and bleeding disorders, and some cancers. Monash University researchers, led by Professor James Whisstock and Associate Professor Paul Coughlin, together with colleagues at the Australian Synchrotron have shown how the protein plasminogen is converted into plasmin, an enzyme that removes disease-causing clots and clears up...

Substance In Cancer Medicine May Help Prevent Heart Attacks
2011-11-24 06:00:51

Researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden have been using a substance found in cancer and epilepsy drugs to help stimulate the body´s natural defense mechanism against blood clots. The body contains a system that helps break down blood clots before they can damage the heart, called the fibrinolytic system. This system “sprays” an enzyme on the clot before it can stop blood flow to the heart, causing a heart attack. This system can be...

2011-02-10 06:00:00

SEATTLE, Feb. 10, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that research on the antifibrinolytic agents it is developing has been published in the February 11, 2011 issue of the Journal of Biological Chemistry and selected by the editors as one of the top one percent of papers reviewed by the Journal in terms of significance and overall importance. This work from the laboratory of S. Paul Bajaj, Ph.D., demonstrates that unique antifibrinolytic agents can be...